B+
Bull case
25%
Probability
Target price
$6.30
Analysis reference price unavailable
Analysis 2026-10-08 · RankAlpha Sentiment Codex
ABUS
Arbutus BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The completed 23% share retirement, July settlement receipt, possible Genevant dividend and progress toward an imdusiran Phase 2b trial support a more constructive view than the prior baseline. The packet's positive deterministic prior and elevated thesis-change score are directionally consistent with the confirmed tender completion.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.6.
What can break
Oversubscription and proration mean most tendered shares were not purchased; the completed $5.00 tender does not support a standing $5.00 floor. [#PR-EARNINGS-2026-10-01] Company final tender results
Momentum
23
Value
55
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $6.30 · Bear $2.80Analysis 2026-10-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.50
Why
Momentum23 · Δ7d -11.2
Value55 · Δ7d -0.2
Sentiment67 · Δ7d +0.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +0.6.
Contradictions & invalidation
- • Oversubscription and proration mean most tendered shares were not purchased; the completed $5.00 tender does not support a standing $5.00 floor. [#PR-EARNINGS-2026-10-01] Company final tender results
- • Phase 2b protocol finalization, initiation, eventual efficacy and safety results, and associated R&D spending remain execution risks. [#PR-2026-08-12] Company Q2 release
- • The buyback consumes $230 million; the post-tender cash balance and anticipated Genevant dividend were not verified.
Catalyst clock
2026-10-31
Post-tender valuation reset
Lead driver: Sentiment · See AI snapshot
Momentum
23
8% active weight
Current posture
7d trendSoftening
Δ7d
-11.2
Δ21d
-45.9
Value
55
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.7
Sentiment
67
45% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
-9.2
Why this grade
Composite grade B. Momentum 22.9 / Value 55.2 / Sentiment 67.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-10-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-10-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$832.04M
Beta
0.72
Shares Out
198.11M
P/E (TTM) · Derived
-24.0
P/S (TTM)
62.02
P/FCF (TTM) · Derived
-20.27
Rev YoY
-90.6%
EPS YoY
-298.5%
Gross Margin
+100.0%
Op Margin
+81.1%
Net Debt
-$87.28M
Current Ratio
81.42
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data